NCT02330783 2017-05-09Efficacy and Safety of Bevacizumab Plus Sorafenib for the Third-line Treatment in Metastatic Renal Cancer PatientsPeking University Cancer Hospital & InstitutePhase 2 Unknown106 enrolled